Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS.

Cancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18.

2.

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Ahluwalia MS, de Groot J, Liu WM, Gladson CL.

Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014. Review.

3.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, Ocaña A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

4.

Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Kalman B, Szep E, Garzuly F, Post DE.

Neuromolecular Med. 2013 Jun;15(2):420-34. doi: 10.1007/s12017-013-8229-y. Epub 2013 Apr 11. Review.

PMID:
23575987
5.

The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.

Guo G, Narayan RN, Horton L, Patel TR, Habib AA.

Curr Cancer Drug Targets. 2017;17(3):297-302. doi: 10.2174/1568009616666161215162515. Review.

PMID:
28004613
6.

[SRC kinases in tumor therapy].

Dempke W, Zippel R.

Med Klin (Munich). 2010 Oct;105(10):711-5. doi: 10.1007/s00063-010-1123-y. Epub 2010 Oct 28. Review. German.

PMID:
20981590
7.

Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

de Groot J, Milano V.

J Neurooncol. 2009 Nov;95(2):151-163. doi: 10.1007/s11060-009-9916-2. Epub 2009 May 13. Review.

PMID:
19436954
8.

Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.

Petitprez A, Larsen AK.

Curr Pharm Des. 2013;19(5):958-64. Review.

PMID:
22973964
9.

Fyn: a novel molecular target in cancer.

Saito YD, Jensen AR, Salgia R, Posadas EM.

Cancer. 2010 Apr 1;116(7):1629-37. doi: 10.1002/cncr.24879. Review.

10.
11.

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

Roth P, Weller M.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii14-9. doi: 10.1093/neuonc/nou222. Review.

12.

Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.

Azuaje F, Tiemann K, Niclou SP.

Cell Commun Signal. 2015 Mar 31;13:23. doi: 10.1186/s12964-015-0098-6. Review.

13.

Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X, Wang JM.

Cancer Lett. 2008 Aug 28;267(2):254-61. doi: 10.1016/j.canlet.2008.03.014. Epub 2008 Apr 22. Review.

14.

EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Zahonero C, Sánchez-Gómez P.

Cell Mol Life Sci. 2014 Sep;71(18):3465-88. doi: 10.1007/s00018-014-1608-1. Epub 2014 Mar 27. Review.

PMID:
24671641
15.

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.

Padfield E, Ellis HP, Kurian KM.

Front Oncol. 2015 Jan 29;5:5. doi: 10.3389/fonc.2015.00005. eCollection 2015. Review.

16.

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.

Keller S, Schmidt MHH.

Int J Mol Sci. 2017 Jun 18;18(6). pii: E1295. doi: 10.3390/ijms18061295. Review.

17.

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

An Z, Aksoy O, Zheng T, Fan QW, Weiss WA.

Oncogene. 2018 Jan 11. doi: 10.1038/s41388-017-0045-7. [Epub ahead of print] Review.

PMID:
29321659
18.

Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma.

Villa GR, Mischel PS.

Nat Neurosci. 2016 May 26;19(6):765-7. doi: 10.1038/nn.4302. Review. No abstract available.

PMID:
27227363
19.

Pathway inhibition: emerging molecular targets for treating glioblastoma.

Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M.

Neuro Oncol. 2011 Jun;13(6):566-79. doi: 10.1093/neuonc/nor039. Review.

20.

Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity.

Noch E, Khalili K.

Cancer Biol Ther. 2009 Oct;8(19):1791-7. Review.

Supplemental Content

Support Center